Toceranib | B1542

Toceranib is a potent, cell-permeable, ATP-competitive multi-targeted receptor tyrosine kinase inhibitor that is structurally related to Sunitinib (Cat. No. 2097). It potently inhibits signaling through VEGFR, FGFR, PDGFR, and Kit. Additionally, toceranib blocks the autophosphorylation of both wild type and mutant forms of Kit in response to stem cell factor, resulting in cell death. It is active in vivo and is commonly used against solid tumors in dogs.

Toceranib is a potent, cell-permeable, ATP-competitive multi-targeted receptor tyrosine kinase inhibitor that is structurally related to Sunitinib (Cat. No. 2097). It potently inhibits signaling through VEGFR, FGFR, PDGFR, and Kit.

B1542 | Toceranib DataSheet

Alternate Name/Synonyms: 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide; PHA 291639, SU 11654

Appearance: Orange solid

Formulation: N/A

CAS Number: 356068-94-5

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₂₂H₂₅FN₄O₂

Molecular Weight: 396.46

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~ 4 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: An ATP-competitive multi-targeted receptor tyrosine kinase inhibitor

MDL Number: N/A

PubChem CID: 5329106

SMILES: CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)C=C3C4=C(C=CC(=C4)F)NC3=O

InChi: InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-

InChi Key: SRSGVKWWVXWSJT-ATVHPVEESA-N